Aurobindo Pharma completes acquisition of US-based Lannett Company

Listed Co AcquisitionStrategic Transactions View source PDF

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.8%1-day move

₹1538.30

prior close

₹1576.60

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.1-0.1-0.2-0.4+0.8+1.6+5.1+3.6+2.9+2.9+3.0———

Up moveDown movePending

AI summary

Aurobindo Pharma's wholly owned US subsidiary APUSA has completed the acquisition of Lannett Company Inc. from Lannett Seller Holdco, effective June 29, 2026. The deal received US FTC approval on June 18, 2026. Lannett now becomes a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC. Over 400 Lannett employees will join APUSA, and integration begins immediately.

Likely market impact

Strengthens Aurobindo's US generics footprint; adds Lannett's product portfolio, manufacturing capacity, and about 400 employees.